YME1L1

Across TCGA pan-cancer cohorts, YME1L1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated YME1L1 data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher YME1L1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated YME1L1 expression acts as an unfavorable survival marker, although some lineages such as LSCC and GBM show a favorable association.

LSCC, LUAD, and GBM are the cancer types where YME1L1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Quartile	II,III,IV	0.929	0.511	.014	9	view →
LUAD	DFS	Median	II,III,IV	0.232	0.772	.007	7	view →
GBM	DFS	Quartile	All	0.843	0.437	.009	7	view →
COAD	DFS	Median	IV	0.432	0.944	.012	6	view →
HNSC	DFS	Quartile	All	0.315	0.852	.010	6	view →
CCRCC	DFS	Quartile	III,IV	0.355	0.754	.031	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

YME1L1–LSCC (DFS)

Open the LSCC breakdown →